If approved, healthcare professionals will be able to prescribe either Xarelto 10mg after patients have received at least 6 months of standard anticoagulation therapy Janssen has submitted a ...
Pexidartinib is an oral small molecule that is believed to work by inhibiting colony stimulating factor-1 receptor (CSF1R). Both doses of Xarelto (10mg and 20mg) were superior to aspirin (100mg) in ...
RARITAN, NJ, Janssen Pharmaceuticals, Inc. announced today the U.S. Food and Drug Administration (FDA) has approved XARELTO® to reduce the risk of stroke and systemic embolism in patients with ...
The FDA approved the first generics of the direct oral anticoagulant rivaroxaban, the agency announced on Tuesday. Rivaroxaban 2.5 mg tablets from Lupin and Taro are now considered therapeutic ...
The Food and Drug Administration has given Janssen the green light for two pediatric indications for Xarelto (rivaroxaban): the treatment of venous thromboembolism and reduction in the risk of ...
ORLANDO -- New data from the so-called Einstein Jr. collaborative confirm dosing regimens for a pediatric oral suspension of rivaroxaban (Xarelto), suitable for children ranging from 2.6 to 70 kg in ...
Aurobindo has obtained the Food and Drug Administration’s green light for rivaroxaban tablets, 2.5 mg, which is the generic of Janssen’s Xarelto. Rivaroxaban tablets are used to reduce the risk of ...
In patients with venous thromboembolism who have completed 6–12 months of anticoagulation therapy and are in equipoise for continued anticoagulation, rivaroxaban treatment was associated with lower ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results